Blue Sage Health Consulting

11/13/2025

A recent study published in Frontiers in Child and Adolescent Psychiatry led by psychiatrist Rosalie Greenberg examined the medical charts of 37 children and adolescents—ages 9 to 17—diagnosed with pediatric bipolar disorder in a Lyme-endemic region of New Jersey.
Strikingly, 92% of these patients (34 out of 37) showed evidence of tick-borne disease exposure. And more than three-quarters of the cohort demonstrated confirmed tick-borne infections.

Study: https://www.frontiersin.org/journals/child-and-adolescent-psychiatry/articles/10.3389/frcha.2025.1685016/full

Article: https://www.lymedisease.org/child-psychiatric-symptoms/

In the Lyme world, these stories surface again and again. A child who was thriving suddenly shifts—mood swings, anxiety, trouble focusing, even

11/11/2025

Blue Sage Health Winter Offerings ❄️💜

🌀Professional Networking Mini-Series
🌀Community Integration Circles
🌀Professional Consultation Group
🌀Spring Wellness Retreat
🌀welcoming New and Returning Clients

https://mailchi.mp/b8f864ab4765/psychedelic-therapy-training-program-applications-due-dec-21066017?e=ee9df73d01

11/07/2025

Psychedelic Integration Group-Winter 2026
Date: Jan 6, Feb 3 and March 3
Time: 6:15-7:30pm ET
Cost: $35
RSVP to bluesagehealth@gmail.com

Would you like help processing your psychedelic experience in a group setting with professional facilitation?

This group is for those who have already had full-dose psychedelic experiences; it is not for people who are microdosing, just curious, or looking for information.

Psychedelic integration offers non-judgmental support to those who have previously explored altered states of consciousness through psychedelic substances.

It is a safe space to share your experience and process. The group can help you find meaning/words for inexplicable visions, understand difficult trips, and translate the insights into daily steps that will enable you to release, heal, grow, find your purpose and live your truth.

You can come to one or all of these groups. Please register in advance.

Register: https://forms.gle/NZnb1hcko7ryCzG46

11/07/2025

Psychedelic Mini-Series and Networking for Professionals

Description:
This is a 3-part mini-series lecture, discussion, and professional networking in Ann Arbor.

This mini-series is designed for healthcare professionals and healing arts professionals....this includes therapist, counselors, social workers, psychologist, doctors, nurses, physician assistants, nurse practitioners, mental health therapists, addiction counselors, occupational therapists, physical therapists, naturopaths, massage therapists, somatic therapists, etc. Clergy may also attend.

Topics covered:

-What do I need to know about psychedelics in order to work with clients who may use them?

-What do I need to know legally to keep myself safe?

-How to help clients integrate their psychedelic experiences?

-Should I do my own psychedelic journey?

-Is psychedelic therapy a career path for me?

-When might psychedelics be legal for treatment?

-Network with others to build a strong and diverse professional network.

-Connect with others to find resources and complementary healing practices.

Dates: Tuesdays Jan 20, Feb 17 and March 17
Time: 6:15pm-7:45pm
Location: Blue Sage Health Consulting at 1829 W. Stadium Blvd, Suite 700, Ann Arbor, MI 48103 (Virtual participants are welcome but networking will be limited)

Cost: $325 per person for the whole 3-part series

Registration is required in advance. Space is limited.
Facilitated by Julie Barron

To Register: https://forms.gle/yFiYHsmRNnL2fGoT6

10/27/2025

BPL-003, an intranasal mebufotenin (5-MeO-DMT) benzoate was just granted Breakthrough Therapy designation status by the FDA. It shows promise for Treatment Resistant Depression with rapid and durable effects from a single dose and a 2 hour session window.

https://www.beckleypsytech.com/posts/atai-life-sciences-and-beckley-psytech-announce-fda-breakthrough-therapy-designation-granted-to-bpl-003?fbclid=Iwb21leANsXlVjbGNrA2xeSWV4dG4DYWVtAjExAAEeNw1cLEAf8xoBlGMbH-0NZG13YHVZhBjQwMOfaLHfASLwQInCYkpawzJcUzg_aem_cHJQye36y8A8vp8SsZvxZg.

Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression.

10/18/2025

I continue to follow the ancient wisdom and newest scientific research about Saffron (crocus sativus plant) for it's anti depressant, anti-anxiety, anti tumor, anti-inflammatory, anti hypertensive, cardio-protective, neuroprotective, and antioxidant effects.
I find it fascinating!

This is a great and thorough paper:
"Exploring the Potential of Saffron as a Therapeutic Agent in Depression Treatment: A Comparative Review"
https://pmc.ncbi.nlm.nih.gov/articles/PMC11426294/

1. Antioxidant Effects: Saffron exhibits potent antioxidant and free radical scavenging activities due to the presence of carotenoids such as crocin and crocetin. It inhibits lipid peroxidation and enhances antioxidant enzyme activities and helps protect cells from oxidative stress-induced damage, preserving cellular integrity and function. A study revealed that after saffron supplementation, the active compound crocin significantly reduced levels of oxidative stress markers, malondialdehyde (MDA), and total antioxidant capacity (TAC) [65,69,70].

2. Anti-inflammatory Effects: It exerts anti-inflammatory effects by inhibiting proinflammatory cytokines and enzymes such as Cyclooxygenase-2 (COX-2) and intercellular Nitrogen Oxygen Species (iNOS), reducing inflammatory conditions at the cellular level. Saffron and crocin exert neuroprotective effects by reducing oxidative stress and inflammatory responses, which shows their potential for mitigating inflammation-related damage in patients with brain injury [71].

3. Anti-Atherogenic Effects: In saffron, compounds such as crocetin help decrease the levels of cardiac markers such as Lactate dehydrogenase (LDH), Creatine kinase (CK), and MDA, which are the indicators of cardiovascular risk factors. These effects contribute to the potential of saffron in preventing atherosclerosis and cardiovascular diseases. Saffron extract has a plaque-stabilizing effect in both the early and advanced stages of atherosclerosis [72,73].

4. Anti-Apoptotic Effects: The bioactive constituents of safranin help prevent programmed cell death, thereby promoting cell survival and tissue integrity. This antiapoptotic activity is crucial in various disease conditions where excessive cell death occurs [65].

5. Antihypertensive Effects: Safranal and crocetin help control blood pressure by modulating cellular mechanisms involved in vascular tone and blood pressure regulation. Saffron may exert its antihypertensive effects through various mechanisms, including increasing nitric oxide (NO) concentrations, enhancing antioxidant properties, regulating endothelial function, and attenuating the NF-kappa B pathway, through which its supplementation is potentially useful for blood pressure regulation [65,74].

6. Hypolipidemic Effects: Hypolipidemic effects help reduce triglycerides and cholesterol levels within the cells, thereby improving lipid profiles and reducing the risk of cardiovascular diseases associated with dyslipidemia. In 2024, researchers conducted a systematic review and meta-analysis to investigate the effects of saffron supplementation on glycemic outcomes in patients with diabetes. The study revealed that saffron was effective in reducing fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c), indicating that it may be useful in controlling blood sugar levels in diabetic patients. However, the study noted that there was significant variation in the quality of the methodology used, indicating that more well-designed clinical trials are needed to further investigate the potential benefits of saffron. Another review published in 2024 focused on the effects of saffron on the CNS, particularly its potential as a nutraceutical for treating common CNS diseases [20,53].

08/28/2025

The Blue Sage Professional Consultation Group is an incredible mix of therapists, clergy and doctors who meet every couple weeks to discuss topics in psychedelic healing like ethics, research, client care, medication interactions, palliative care, somatic work, etc. It's quite special!
🙌🏽💙🍄🌱

08/09/2025

If you’re working with clients taking GLP-1 agonists and planning to take mushrooms, be cautious. Test doses may underperform. Delayed peaks can confuse expectations and schedules. Stronger-than-expected effects can hit suddenly hours later.

This is an area that is ripe for further study.

In the meantime, sublingual psilocin offers a compelling alternative, rooted in pharmacology, supported by anecdote, and increasingly accessible.

More people than ever are taking GLP-1 receptor agonists—drugs like Ozempic (semaglutide), Wegovy, and Mounjaro. These medications, originally developed for type 2 diabetes, are now widely prescribed for weight loss. They work by mimicking the body’s natural GLP-1 hormone, which regulates blood ...

07/29/2025

Psilocybin Extends Human Cell Lifespan by Over 50%—New Study Unveils Surprising Longevity Potential

Psilocybin, the psychedelic compound traditionally known for its mind-altering effects, may have a powerful new application: slowing down the biological aging process.

In a groundbreaking study published in npj Aging, scientists from Emory University and Baylor College of Medicine found that psilocybin extended the lifespan of human cells by more than 50%. The researchers treated skin and lung fibroblasts with psilocin—the active form of psilocybin—and observed significantly delayed cellular senescence.

But it gets even more intriguing.

Aging mice given monthly doses of psilocybin had their survival rates jump from 50% to 80% over a 10-month period. The treated mice not only lived longer, but also showed fewer visible signs of aging such as fur whitening and hair loss.

This is the first direct experimental evidence that psilocybin may offer longevity benefits, pushing its potential beyond mental health treatment and into the realm of anti-aging science.

🧪 While further studies are needed to explore long-term effects and optimal dosing, this discovery opens a bold new frontier: psychedelics for life extension.

📖 Source:
Kato, K., Kleinhenz, J.M., Shin, YJ. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging 11, 55 (2025).

Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable clinical evidence for its therapeutic potential to treat various psychiatric and neurodegenerative indications. However, the underlying molecular mechanisms remai...

07/17/2025

I appreciate Dr Goldstein's blog about a recently.published JAMA research paper claiming potential liver damage from "low dose" CBD.

It's really important to know the facts instead of just reading the headline on this research.

-The study and previous studies have showed temporary elevated liver enzymes In 5% of people taking 350 mg of isolate CBD (they are claiming that is "low dose").

Actually, 350mg of CBD is a very high dose! Most people that we work with are taking whole plant CBD (not isolate) and are taking between 15mg and 60mg/day.

Dr Goldstein reports that in her patients, any elevated liver enzymes from people who are needing to actually take high dose CBD are completely reversible after stopping CBD.

If you are a physician, it may be important to monitor liver enzymes of people who are needing to take high dose CBD isolate. In the general dosing category, not a concern.

Bonni Goldstein, MD, critiques a new FDA study.